Liu Xiaolong, Lu Jianguo, Dong Xinyu, Zhang Yizhuo, Jiang Guixing, Cao Yanlong, Hong Defei
Department of General Surgery, Sir Run Run Shaw Hospital & Zhejiang University School of Medicine, Hangzhou, China.
Department of General Surgery, Tangdu Hospital & Fourth Military Medical University, Xi'an, China.
Ann Med. 2025 Dec;57(1):2512436. doi: 10.1080/07853890.2025.2512436. Epub 2025 Jun 5.
Pancreatic cancer is very difficult to detect in its early stages, and its rapid progression and poor prognosis make it a significant therapeutic challenge. Existing treatment modalities, whether standalone or combined, offer limited efficacy, highlighting an urgent need for more effective and less toxic therapeutic strategies.
We analyze six cases of pancreatic cancer, each undergoing a novel treatment regimen integrating chemotherapy, targeted therapy, immune therapy, and icaritin.
The outcomes demonstrate varying degrees of improvement in all cases. Partial responses were observed in cases 1 and 3, with some tumor shrinkage. Cases 4 and 5 showed limited relief following a slight decrease in tumor size. In cases 2 and 6, no significant progression of the lesion was observed. These results highlight the potential efficacy of this multifaceted approach.
Integrating icaritin with chemotherapy, immunotherapy, and/or targeted therapies shows potential as an exploratory approach in managing advanced, locally progressive, or metastatic pancreatic cancer, though further validation is required.
胰腺癌在早期很难被检测到，其快速进展和不良预后使其成为一项重大的治疗挑战。现有的治疗方式，无论是单独使用还是联合使用，疗效都有限，这凸显了对更有效且毒性更小的治疗策略的迫切需求。
我们分析了6例胰腺癌病例，每例均接受了一种整合化疗、靶向治疗、免疫治疗和淫羊藿素的新型治疗方案。
结果显示所有病例均有不同程度的改善。病例1和病例3出现部分缓解，肿瘤有一定程度缩小。病例4和病例5在肿瘤大小略有减小后显示出有限的缓解。病例2和病例6未观察到病变有明显进展。这些结果凸显了这种多方面治疗方法的潜在疗效。
将淫羊藿素与化疗、免疫治疗和/或靶向治疗相结合，作为一种探索性方法在治疗晚期、局部进展期或转移性胰腺癌方面显示出潜力，不过仍需要进一步验证。
